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Maternal antibody prevents the use of live, attenuated measles vaccine (LAV) before 6–9 months of age, but vaccinated 6-month-old infants
can mount a T cell response. An infant macaque model was used to study the immune response to LAV in the newborn in the presence or absence
of maternal antibody. Four newborn monkeys without detectable maternal antibody and 9 newborns with passive measles antibody were
vaccinated with LAV. Only the infants without passive antibody seroconverted after vaccination and 3 of 4 of these infants also developed
measles-specific interferon γ+ T cells. The monkeys were challenged with wild-type measles virus at 5 months of age, and 7 of 9 infants
vaccinated in the presence of passive antibody had systemic infection and skin rash, while 3 of the 4 infants vaccinated in the absence of passive
antibody were protected from viremia and rash. This suggests that the newborn can respond to LAV but that maternal antibody suppresses the
priming of both humoral and cellular immunity at birth.
© 2006 Elsevier Inc. All rights reserved.Keywords: Infant; Immunity; Vaccine measles; Nonhuman primateIntroduction
The live, attenuated vaccines (LAV) used to control measles
virus (MV) are among the safest and most efficacious vaccines
in use today. Use of LAV has dramatically reduced the
incidence of measles worldwide, and some areas have reported
elimination of endemic transmission of MV. However, one of
the drawbacks of LAV is that infants that are vaccinated while
they still have maternal antibodies have low seroconversion
rates (Albrecht et al., 1977). Many developing countries still
have intense MV transmission, especially in children less than 1
year of age. In these countries, measles claims the lives of an
estimated 700,000 infants and young children annually. In an
attempt to protect infants from measles, LAV is given as early as
6 months of age and routinely at 9 months of age (Burstrom et⁎ Corresponding author. Fax: +1 530 752 2880.
E-mail address: mbmcchesney@ucdavis.edu (M. McChesney).
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doi:10.1016/j.virol.2006.02.029al., 1995). However, this strategy results in seroconversion rates
that are significantly lower than the rate of 94%, which is
achieved by administering the first dose of LAVafter 12 months
of age (van den Hof et al., 2002). The lower seroconversion
rates following early administration of LAV can lead to an
accumulation of susceptible children. Therefore, it would be
desirable to have a new vaccination strategy that could protect
infants in measles-endemic countries during the first year of life
and that would not interfere with later vaccination with LAV at
12 months.
Recent studies involving human infants vaccinated with
LAV at 6 months in the presence or absence of maternal
antibodies have shown that these infants have cellular immune
responses that are similar to those of infants 12–15 months of
age (Bertley et al., 2004; Gans et al., 2001, 2003). When
infants at 6, 9 and 12 months were compared in their ability to
respond to LAV, it was found that maternal antibodies did not
inhibit T cell interferon γ responses, regardless of age. As
expected, maternal antibodies inhibited humoral responses in
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that, regardless of detectable maternal antibody titers, infants at
6 months had a deficient humoral immune response. Since
LAV was able to prime a cellular immune response in 6-month-
old infants, we asked whether LAV could prime a protective
cellular response when administered to newborns in the
presence of maternal antibodies.
To date, only three vaccines are given to newborn infants: for
hepatitis B, polio and tuberculosis. The two central issues
regarding the development of additional vaccines for newborns
are the extent to which maternal antibodies inhibit the
immunogenicity of the vaccines and the capacity of newborns
to mount specific, protective immune responses. In this study,
we used a newborn rhesus monkey model of measles
vaccination to test whether infants administered LAV at birth
can mount protective immunity, including neutralizing
antibodies.
Results
To study the immune response following vaccination with
LAV in the presence of maternal antibody, a genetically out-
bred macaque model, previously shown to mirror measles
pathogenesis and immunosuppression, was used (McChesney
et al., 1997; van Binnendijk et al., 1997). The rhesus macaque
colony at the California National Primate Research Center is
routinely vaccinated against measles. Therefore, at birth,
newborn macaques were screened for maternal antibodies
using an anti-measles nucleoprotein IgG ELISA as described
(Hummel et al., 1992). Four newborns had maternal antibodies
(Table 1) due to either prior measles infection or vaccination of
the dams. To mimic maternal antibody effects, 5 seronegative
newborns were administered 3.5 ml of measles immune
globulin (MIG) subcutaneously (SQ) at 48 h prior to
vaccination (Table 1). MIG is a heat-inactivated serum pool
from previously infected animals that has a reciprocal neu-
tralizing titer of 5120 by 50% endpoint titration and has beenTable 1
Antibody and T cell responses after MV vaccination and skin rash after MV
challenge
Passive
antibody
Monkey Reciprocal neutralizing titer (month) T
cells a
Skin
rash
0 1 2 4 5 b
Maternal
antibody
32331 80 20 40 40 <10 <25 +
32306 160 <10 <10 <10 <10 <25 −
32299 320 80 20 40 <10 <25 +
32294 160 40 40 10 <10 <25 +
MIG 32289 80 80 40 10 <10 <25 −
32293 80 40 40 <10 <10 <25 +
32301 640 80 40 <10 <10 <25 +
32303 80 80 20 <10 10 <25 +
32313 160 40 40 <10 <10 <25 +
None 32302 <10 2560 ND 1280 1280 30 −
36055 <10 <10 <10 <10 <10 28 +
36067 <10 20 160 40 320 158 −
36075 <10 2560 5120 5120 1280 108 −
a Interferon γ spot forming cells per 106 PBMC.
b 5 months post-vaccination was the day of MV challenge.shown to mimic the effects of maternal antibodies when
administered 48 h prior to vaccination (Zhu et al., 2000). Four
newborn monkeys had no maternal antibodies and were not
administered MIG (Table 1).
Following vaccination, plasma samples were taken at 1, 2,
2.5, 4 and 5 months to test for anti-MV neutralizing antibody.
On the day of vaccination, 9 infants had protective neutralizing
antibody levels of ≥80 and the 4 infants without passive
antibody had titers of≤10 (Table 1). No infant vaccinated in the
presence of maternal antibodies or MIG had detectable antibody
titers 5 months later on the day of challenge (Table 1, 5 months).
In contrast, 3 of the 4 infants vaccinated without passive
antibody had neutralizing titers of 20–2560 at 1 month post-
vaccination and 320–1280 at 5 months (Table 1). This shows
that, as previously described, maternal antibodies inhibit LAV
from inducing MV-specific antibody responses but newborn
monkeys can, in the absence of maternal antibody, make a
protective humoral response to LAV. MV nucleoprotein-
specific IgM was assayed from samples at 1 month post-
vaccination by an antibody capture method as described
(Erdman et al., 1991). An MV-specific IgM response was
detected in 5 of the 9 infants with passive antibody at 1 month
following vaccination (data not shown), suggesting that direct B
cell priming could occur in the presence of maternal antibody.
Peripheral blood mononuclear cells (PBMC) were isolated at
1, 3 and 5 months post-vaccination for detection of a cellular
immune response, MV antigen-stimulated production of
interferon γ. Infants vaccinated in the presence of maternal
antibody or MIG did not develop a cellular response to MV at
any time point tested (Table 1). In contrast, 3 of 4 infants
vaccinated in the absence of passive antibody had a weak T cell
response following vaccination at 1 or more of 3 time points
tested (Table 1). Therefore, administration of LAV at birth, in
the presence of passive antibody, inhibited cellular immunity.
At 5 months of age, all infant macaques were challenged
intranasally with pathogenic MV. Seven of 9 infant macaques
vaccinated in the presence of passive antibody had high-level
viremia (Fig. 1) and these infants developed the typical measles
skin rash that has previously been observed in infected
macaques (McChesney et al., 1997). In contrast, 3 of 4 infant
macaques vaccinated in the absence of passive antibody had no
detectable viremia or rash. Two infant macaques in the passive
antibody group had prolonged viremia, detectable at 1 month
post-challenge (Fig. 1, monkeys 32331 and 32293), and 2
monkeys with passive antibody, 32289 and 32294, were
protected from systemic infection and rash. Both animals had
a detectable IgM response 1 month post-vaccination, although
neither had detectable pre-challenge cellular immunity nor
neutralizing antibody responses, again suggesting that these
animals were primed but their immunity was undetectable by
our methods.
Because they had no detectable neutralizing antibody on the
day of challenge, it was important to determine that the infant
macaques vaccinated in the presence of passive antibody were
able to make an immune response to MVand were not tolerized
to the virus by vaccination with LAV at birth. Seven of the 9
infants vaccinated in the presence of passive antibody had
Fig. 1. Viremia following measles virus challenge at 5 months of age. Viral loads
were quantified by endpoint dilution culture of PBMC at 7, 14 and 28 days post-
challenge as described (Premenko-Lanier et al., 2003). The upper graph depicts
the mean viral titers of 5 infants that received a control DNA vaccine and that
were also challenged at 5 months of age (Premenko-Lanier et al., 2003).
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14 post-MV challenge (data not shown).
Discussion
This is the first demonstration of the use of LAV in a
newborn primate. We found that passive antibody in this setting
inhibited a cellular immune response to MV in addition to the
known effect on seroconversion. This result was unexpected
and requires further investigation of possible cellular mechan-
isms. In this animal model, 80% of infants vaccinated with LAV
in the presence of passive antibody became infected, some with
altered or prolonged viremia. The inability to develop a cellular
immune response to LAV in infant macaques observed in this
study stands in marked contrast to the effect of a measles DNA
vaccine given to newborn monkeys in the presence of passive
antibody (Premenko-Lanier et al., 2003). In that study, bothcellular immunity and protection from systemic infection were
effectively induced in the presence of passive antibody. Two
possible mechanisms for the inhibition of cellular immunity by
maternal antibody observed in the present experiment, and not
observed with the measles DNA vaccine, would be complete
neutralization of the LAV virus and/or an inhibitory effect of
immune complexes on antigen processing and presentation to
naive T cells. LAV virions or viral proteins complexed to
maternal MV-specific IgG, by binding to FcγRIIB on dendritic
cells (Kalergis and Ravetch, 2002), could suppress T cell
priming to MVantigens. The latter hypothesis could be tested in
an in vitro assay of T cell priming with immune complexes and
dendritic cells (Regnault et al., 1999).
The ability of the newborn infant to mount protective
immune responses to infection or vaccination is a subject of
increasing interest, and animal models have been important in
this regard (Chappuis, 1998; Siegrist et al., 1998). Because most
women of child-bearing age have immunity to measles,
congenital or neonatal infections are not common. Congenital
measles has occurred in rare instances when an MV-seroneg-
ative mother was infected just prior to delivery. Either an
uncomplicated or a severe disease course was observed in the
infant (Atmar et al., 1992; Betta Ragazzi et al., 2005). In
uncomplicated, congenital MV infection, infected newborns
had the ability to mount protective immunity and clear the
infection.
Materials and methods
Animals and virus
Colony-bred male and female newborn rhesus macaques
were housed in a nursery, in accordance with the guidelines of
the Committee on Care and Use of Laboratory Animals,
National Resources Council. Newborn monkeys were vacci-
nated SQ with LAV (titer ≥103 TCID, Attenuvax, Merck and
Co., NJ). This is the standard dose and route for human infants.
It was noted that administration of LAV was followed by
moderate to severe diarrhea and dehydration in some infant
macaques, requiring supplemental fluid therapy. At 5 months of
age, the infants were challenged intranasally with 104.5 TCID50
of pathogenic MVDavis 87 (McChesney et al., 1997). This is a
non-lethal challenge, and the monkeys recover from measles
within 30 days. MV viremia was quantified in PBMC by
endpoint dilution co-culture with Raji cells as described
(McChesney et al., 1997).
MV-specific immune responses
Antibody titers were measured by 50% viral antigen
reduction in Vero cells, as described (Zhu et al., 1997), and
confirmed by plaque assay (data not shown). The serum
neutralizing titer is reported as the highest dilution showing a
50% reduction in viral antigen. Cellular immunity was
measured using an interferon γ ELISPOT assay as previously
described (Premenko-Lanier et al., 2003). PBMC were
stimulated for 16 h with whole viral antigen, medium control
432 M. Premenko-Lanier et al. / Virology 350 (2006) 429–432or PMA and ionomycin. A positive response is defined as ≥25
spots per million PBMC and 2 standard deviations above the
mean spot number of medium control wells.
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